# A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

> **NCT04197817** · PHASE1 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 84 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** JS002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04197817
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-11
- **Primary completion:** 2018-08-14
- **Final completion:** 2018-08-14
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2019-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04197817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04197817, "A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04197817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*